Clinical trials: Nonarteritic Ischemic Optic Neuropathy
Post-COVID-19 Condition, Ulcerative Colitis
Emerging Indications for Hyperbaric Oxygen Treatment
This study will evaluate the effectiveness of hyperbaric oxygen therapy (HBOT) on treating emerging indications (i.e., conditions that have shown to potentially benefit from HBOT) using the Multicenter Registry for Hyperbaric…
- Conditions
- Post-COVID-19 Condition, Ulcerative Colitis, Crohn Disease, Calciphylaxis
- Trial name
- NCT07240649
- Testing
- Hyperbaric oxygen treatment (HBOT), 100% Oxygen
- Volunteers
- 100 people
- Sponsor
- Jay C. Buckey Jr.
Nonarteritic Anterior Ischemic Optic Neuropathy
Ranibizumab Therapy for Non-arteritic Ischemic Optic Neuropathy
The purpose of this study is to explore the safety and efficacy of ranibizumab to treat non-arteritic ischemic optic neuropathy based on clinical and anatomical findings.
- Trial name
- NAION (NCT00561834)
- Testing
- ranibizumab
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- University of Colorado, Denver
Ischemic Optic Neuropathy
ENDOTHELION Study Group: Effect of Bosentan in NAION Patients
Acute ischemic optic neuropathy are the second leading cause of optic neuropathy after glaucoma in the population aged over 50 years.
- Trial name
- ENDOTHELION (NCT02377271)
- Testing
- bosentan
- Where
- 7 sites in France
- Volunteers
- 86 people
- Sponsor
- University Hospital, Grenoble
Nonarteritic Anterior Ischemic Optic Neuropathy
Effect of Levodopa-Carbidopa on Visual Function in Patients With Recent-Onset Nonarteritic Anterior Ischemic Optic Neuropathy
Purpose: There are some controversies about the effect of Levodopa-Carbidopa on treatment of non-arteritic anterior ischemic optic neuropathy (NAION).
- Trial name
- NCT00432393
- Testing
- levodopa-carbidopa
- Where
- Iran
- Sponsor
- Shahid Beheshti University of Medical Sciences
Optic Atrophy, Non-arteritic Anterior Ischemic Optic Neuropathy
Safety Study of a Single IVT Injection of QPI-1007 in Chronic Optic Nerve Atrophy and Recent Onset NAION Patients
This is an open-label, dose escalation, safety, tolerability and pharmacokinetic study, where active study drug (QPI-1007) will be given to all patients who participate.
- Trial name
- NCT01064505
- Testing
- QPI-1007 at various doses
- Where
- 28 sites in United States, Israel
- Volunteers
- 48 people
- Sponsor
- Quark Pharmaceuticals
Non-arteritic Ischemic Optic Neuropathy, Optic Disk Drusen
NA-AION Risk Factors: New Perspectives
The purpose of the study is to use new diagnostic methods (OCT and OCT-A) to shed light on risk factors for the development of NA-AION.
- Trial name
- NARROW (NCT05305079)
- Where
- 20 sites in United States, Australia and 7 more
- Volunteers
- 179 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Nonarteritic Anterior Ischemic Optic Neuropathy
A Study to Determine if There is a Possible Association Between NAION and Phosphodiesterase Type 5 (PDE5) Inhibitors
Study H6D-MC-LVHQ is an observational, non-interventional, multi-center, prospective, case-crossover study to evaluate the possible association between the use of phosphodiesterase type 5 (PDE5) inhibitors and the risk of acute…
- Trial name
- NCT01131104
- Testing
- PDE5 Inhibitors
- Where
- 44 sites in United States
- Volunteers
- 345 people
- Sponsor
- Eli Lilly and Company